ClinicalTrials.gg
CompletedNCT01568866ENDEAVORUpdated Nov 14, 2022Results posted

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

A Phase 3 interventional study of Carfilzomib and Bortezomib in Multiple Myeloma, sponsored by Amgen. Completed at 241 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
929
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
2nd of 113
929 · median 54
Started
2012
with 10 others
Phase 3
15 of 113
1 open now
Registered
24th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 11 that started in 2012, is one of 15 in phase 3, and was the 24th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • multiple myeloma
  • relapsed multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Multiple myeloma with relapsing or progressing disease at study entry.
  2. Patients must have evaluable multiple myeloma with, at least one of the following (assessed within 21 days prior to randomization):

    • Serum M-protein ≥ 0.5 g/dL, or
    • Urine M-protein ≥ 200 mg/24 hour, or
    • In patients without detectable serum or urine M-protein, serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal serum kappa/lamda ratio, or
    • For immunoglobulin (Ig) A patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL).
  3. Patients must have documented at least partial response (PR) to at least 1 . PR documentation can be based on Investigator assessment.
  4. Received 1, but no more than 3 prior treatment regimens or lines of therapy for multiple myeloma. (Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as one line of therapy).
  5. Prior therapy with Velcade is allowed as long as the patient had at least a PR to prior Velcade therapy, was not removed from Velcade therapy due to toxicity, and will have at least a 6 month Velcade treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not in the proteasome inhibitor class during this 6 month Velcade treatment-free interval).
  6. Prior therapy with carfilzomib is allowed as long as the patient had at least a PR to prior carfilzomib therapy, was not removed from carfilzomib therapy due to toxicity, and had at least a 6-month carfilzomib treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not in the proteasome inhibitor class during this 6 month carfilzomib treatment-free interval). The exception to this is patients randomized or previously randomized in any other Onyx-Sponsored Phase 3 trial.
  7. Males and females ≥ 18 years of age.
  8. (ECOG) Performance Status of 0 to 2.
  9. Adequate hepatic function within 21 days prior to randomization, with \< 1.5 times the (ULN), and (AST) and alanine aminotransferase (ALT) \< 3 times the ULN.
  10. (LVEF) ≥ 40%.
  11. (ANC) ≥ 1000/mm³ within 21 days prior to randomization. Screening ANC should be independent of growth factor support for ≥ 1 week.
  12. ≥ 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.
  13. count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization. Patients should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.
  14. Calculated or measured (CrCl) of ≥ 15 mL/min within 21 days prior to randomization. Calculation should be based on standard formula such as the Cockcroft and Gault:

    [(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if female.

  15. Written in accordance with federal, local, and institutional guidelines.
  16. Female patients of (FCBP) must have a negative serum pregnancy test within 21 days prior to randomization and agree to use an effective method of during and for 3 months following last dose of drug (more frequent pregnancy tests may be conducted if required per local regulations). FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  17. Male patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a FCBP.

Exclusion criteria

Exclusion Criteria:

  1. Multiple Myeloma of IgM subtype.
  2. therapy (prednisone > 30 mg/day or equivalent) within 14 days prior to randomization.
  3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  4. Plasma cell leukemia or circulating plasma cells ≥ 2 × 10\^9/L.
  5. Waldenstrom's Macroglobulinemia.
  6. Patients with known amyloidosis.
  7. Chemotherapy with approved or anticancer therapeutics within 21 days prior to randomization.
  8. Patients randomized or previously randomized in any other Onyx-Sponsored Phase 3 trial.
  9. Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).
  10. Immunotherapy within 21 days prior to randomization.
  11. Major surgery (excluding kyphoplasty) within 28 days prior to randomization.
  12. Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within four months prior to randomization.
  13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at ) or antifungal agents within 14 days prior to randomization.
  14. Known human immunodeficiency () seropositive, infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).
  15. Patients with known cirrhosis.
  16. Second within the past 3 years except:

    • adequately treated basal cell or squamous cell skin cancer
    • carcinoma in situ of the cervix
    • prostate cancer \< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months
    • breast carcinoma in situ with full surgical resection
    • treated medullary or papillary thyroid cancer
  17. Patients with myelodysplastic syndrome.
  18. Significant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days prior to randomization.
  19. Female patients who are pregnant or lactating.
  20. Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).
  21. Patients with to carfilzomib, Velcade, boron, or mannitol.
  22. Patients with to dexamethasone.
  23. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.
  24. Ongoing graft-vs-host disease.
  25. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
929 participants (actual)

Study arms

  • Experimental
    Carfilzomib plus Dexamethasone

    Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.

    Drug: Carfilzomib · Drug: Dexamethasone

  • Active comparator
    Bortezomib plus Dexamethasone

    Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.

    Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Carfilzomib is administered over 30 minutes as an infusion.

    Also known as: PR-171, Krypolis

  • Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)

    Also known as: Velcade

  • Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). Median PFS was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

    Time frame: From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) is defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored at the patient's date of last contact (last known to be alive). Median overall survival was estimated using the Kaplan-Meier method.

    Time frame: From randomization until the data cut-off date of 03 January 2017; median follow-up time for OS was 36.9 and 37.5 months for each treatment group respectively.

  2. Overall Response

    Disease response was evaluated according to the IMWG-URC by the IRC. Overall response was defined as the percentage of participants with a best overall response of partial response (PR), very good PR (VGPR), complete response (CR) or stringent CR (sCR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.

  3. Duration of Response

    Duration of response (DOR) was calculated for participants who achieved an sCR, CR, VGPR, or PR. Duration of response is defined as the time from first evidence of PR or better to confirmation of disease progression or death due to any cause. Median duration of response was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

    Time frame: From randomization until the data cut-off date of 10 November 2014; median follow-up time for DOR was 9.4 and 10.4 months for each treatment group respectively.

  4. Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy

    Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.

    Time frame: From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.

  5. Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)

    A significant reduction in LVEF was defined as a ≥ 10% decrease (absolute change) from baseline in participants whose baseline LVEF is ≤ 55%. For participants with LVEF \> 55% at baseline, a significant change was defined as a decrease in LVEF to \< 45%.

    Time frame: Baseline and 24 weeks

  6. Change From Baseline in Right Ventricular Fractional Area Change (FAC)

    Right ventricular function was assessed by measuring fractional area change (FAC) on echocardiogram.

    Time frame: Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).

  7. Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)

    Pulmonary artery pressure was measured using transthoracic echocardiogram.

    Time frame: Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).

07

Results

Posted Dec 11, 2015

Participant flow

Adults with relapsed multiple myeloma were enrolled between 20 June 2012 and 30 June 2014 at 198 centers in 27 countries in Europe, North America, South America, and the Asia-Pacific region. Results are reported as of the data cut-off date of 03 January 2017, the pre-specified 2nd interim analysis of the secondary endpoint of overall survival.

Participant flow — Overall Study
MilestoneBortezomib + DEXCarfilzomib + DEX
Started465464
Received treatment456463
Completed2748
Not completed438416
Withdrew: Disease progression208183
Withdrew: Adverse event9496
Withdrew: Patient request5571
Withdrew: Physician decision4032
Withdrew: Withdrawal by subject1911
Withdrew: Death1018
Withdrew: Protocol non-compliance24
Withdrew: Lost to follow-up10
Withdrew: Randomized but not dosed91

Outcome measures

PrimaryProgression-free Survival

Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). Median PFS was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

Time frame:
From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively
Reported as:
Median · months
Progression-free Survival
monthsBortezomib + DEXCarfilzomib + DEX
Progression-free Survival9.4 (8.4 to 10.4)18.7 (15.6 to NA)
Statistical analysis
  • Bortezomib + DEX vs Carfilzomib + DEX · Stratified Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.533 · 95% CI 0.437 to 0.651The hazard ratio (carfilzomib/bortezomib) was estimated using a Cox proportional hazards model stratified by prior proteasome inhibitor treatment, lines of prior treatment, ISS stage, and choice of route of bortezomib administration.
SecondaryOverall Survival

Overall survival (OS) is defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored at the patient's date of last contact (last known to be alive). Median overall survival was estimated using the Kaplan-Meier method.

Time frame:
From randomization until the data cut-off date of 03 January 2017; median follow-up time for OS was 36.9 and 37.5 months for each treatment group respectively.
Reported as:
Median · months
Overall Survival
monthsBortezomib + DEXCarfilzomib + DEX
Overall Survival40.0 (32.6 to 42.3)47.6 (42.5 to NA)
Statistical analysis
  • Bortezomib + DEX vs Carfilzomib + DEX · Stratified Log Rank · p = 0.0100 (The multiplicity in testing secondary endpoints was adjusted per group using the sequential Holm procedure to preserve the family-wise error rate at 0.025.) · Hazard ratio (hr): 0.791 · 95% CI 0.648 to 0.964The hazard ratio (carfilzomib/bortezomib) was estimated using a Cox proportional hazards model stratified by prior proteasome inhibitor treatment, lines of prior treatment, ISS stage, and choice of route of bortezomib administration.
SecondaryOverall Response

Disease response was evaluated according to the IMWG-URC by the IRC. Overall response was defined as the percentage of participants with a best overall response of partial response (PR), very good PR (VGPR), complete response (CR) or stringent CR (sCR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.
Reported as:
Number · percentage of participants
Overall Response
percentage of participantsBortezomib + DEXCarfilzomib + DEX
Overall Response62.6 (58.0 to 67.0)76.9 (72.8 to 80.7)
Statistical analysis
  • Bortezomib + DEX vs Carfilzomib + DEX · Stratified Cochran-Mantel-Haenszel · p = < 0.0001 (The multiplicity in testing secondary endpoints was adjusted per group using the sequential Holm procedure to preserve the family-wise error rate at 0.025.) · Odds ratio (or): 2.032 · 95% CI 1.519 to 2.718The odds ratio (carfilzomib/bortezomib) was calculated using the Cochran-Mantel-Haenszel method stratified by prior proteasome inhibitor treatment, lines of prior treatment, ISS stage, and choice of route of bortezomib administration.
SecondaryDuration of Response

Duration of response (DOR) was calculated for participants who achieved an sCR, CR, VGPR, or PR. Duration of response is defined as the time from first evidence of PR or better to confirmation of disease progression or death due to any cause. Median duration of response was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

Time frame:
From randomization until the data cut-off date of 10 November 2014; median follow-up time for DOR was 9.4 and 10.4 months for each treatment group respectively.
Reported as:
Median · months
Duration of Response
monthsBortezomib + DEXCarfilzomib + DEX
Duration of Response10.4 (9.3 to 13.8)21.3 (21.3 to NA)
SecondaryPercentage of Participants With ≥ Grade 2 Peripheral Neuropathy

Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.

Time frame:
From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
percentage of participantsBortezomib + DEXCarfilzomib + DEX
Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy32.0 (27.7 to 36.3)6.0 (3.9 to 8.2)
Statistical analysis
  • Bortezomib + DEX vs Carfilzomib + DEX · Cochran-Mantel-Haenszel · p = <0.0001 (The multiplicity in testing secondary endpoints was adjusted per group using the sequential Holm procedure to preserve the family-wise error rate at 0.025.) · Odds ratio (or): 0.137 · 95% CI 0.089 to 0.210The odds ratio (carfilzomib/bortezomib) was estimated using the unconditional Cochran-Mantel-Haenszel method.
SecondaryPercentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)

A significant reduction in LVEF was defined as a ≥ 10% decrease (absolute change) from baseline in participants whose baseline LVEF is ≤ 55%. For participants with LVEF \> 55% at baseline, a significant change was defined as a decrease in LVEF to \< 45%.

Time frame:
Baseline and 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)
percentage of participantsBortezomib + DEXCarfilzomib + DEX
Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)2.60.0
SecondaryChange From Baseline in Right Ventricular Fractional Area Change (FAC)

Right ventricular function was assessed by measuring fractional area change (FAC) on echocardiogram.

Time frame:
Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).
Reported as:
Mean · percent fractional area change
Change From Baseline in Right Ventricular Fractional Area Change (FAC)
percent fractional area changeBortezomib + DEXCarfilzomib + DEX
Week 12 (n=40, 40)-0.7 ± 5.00-1.1 ± 5.36
Week 24 (n=26, 31)0.7 ± 6.10-1.0 ± 5.03
Week 36 (n=15, 18)-0.5 ± 7.27-0.5 ± 6.38
End of Treatment (n=23, 18)0.4 ± 4.73-1.9 ± 5.47
SecondaryChange From Baseline in Pulmonary Artery Systolic Pressure (PASP)

Pulmonary artery pressure was measured using transthoracic echocardiogram.

Time frame:
Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)
mmHgBortezomib + DEXCarfilzomib + DEX
Week 12 (n=34, 30)0.3 ± 11.722.8 ± 11.44
Week 24 (n=22, 20)1.7 ± 8.473.4 ± 13.63
Week 36 (n=12, 14)4.0 ± 7.242.6 ± 13.55
End of Treatment (n=21, 14)3.4 ± 8.140.9 ± 11.40

Adverse events

Collected over From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 03 January 2017; median duration of treatment was 27 weeks in the bortezomib group and 48 weeks in the carfilzomib treatment group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib—182/456 (39.9%)435/456 (95.4%)
Carfilzomib—272/463 (58.7%)446/463 (96.3%)
Most frequent serious events
Showing 10 of 307
Most frequent serious events
EventBortezomibCarfilzomib
PNEUMONIAInfections and infestations42/45639/463
PYREXIAGeneral disorders3/45619/463
DYSPNOEARespiratory, thoracic and mediastinal disorders1/45618/463
DIARRHOEAGastrointestinal disorders11/4565/463
RENAL FAILURE ACUTERenal and urinary disorders7/45611/463
RESPIRATORY TRACT INFECTIONInfections and infestations5/45610/463
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders3/45610/463
CARDIAC FAILURECardiac disorders3/4569/463
DISEASE PROGRESSIONGeneral disorders6/4568/463
BRONCHITISInfections and infestations2/4568/463
Most frequent other events
Showing 10 of 72
Most frequent other events
EventBortezomibCarfilzomib
ANAEMIABlood and lymphatic system disorders129/456196/463
DIARRHOEAGastrointestinal disorders184/456167/463
FATIGUEGeneral disorders140/456149/463
HYPERTENSIONVascular disorders45/456148/463
PYREXIAGeneral disorders68/456144/463
DYSPNOEARespiratory, thoracic and mediastinal disorders62/456144/463
NEUROPATHY PERIPHERALNervous system disorders130/45649/463
COUGHRespiratory, thoracic and mediastinal disorders72/456128/463
CONSTIPATIONGastrointestinal disorders126/45675/463
INSOMNIAPsychiatric disorders122/456125/463

Baseline characteristics

Intent-to-treat population (all randomized participants)

Age, Continuous
Age, Continuous(years)Bortezomib + DEXCarfilzomib + DEXTotal
Median65.0 (30.0 to 88.0)65.0 (35.0 to 89.0)65.0 (30.0 to 89.0)
Age, Customized
Age, Customized(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
< 65 years210223433
65 -74 years189164353
≥ 75 years6677143
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
Female236224460
Male229240469
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
White353348701
Black9817
Asian5756113
Native Hawaiian/Other Pacific Islander022
Not Reported455095
Multiple101
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
0 (Fully active)232221453
1 (Restrictive but ambulatory)203211414
2 (Ambulatory but unable to work)303262
Stratification Factor: Prior Proteasome Inhibitor Treatment
Stratification Factor: Prior Proteasome Inhibitor Treatment(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
Carfilzomib or bortezomib253252505
No prior carfilzomib or bortezomib212212424
Stratification Factor: Lines of Prior Treatment
Stratification Factor: Lines of Prior Treatment(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
1 line229231460
2 or 3 lines236233469
Stratification Factor: International Staging System (ISS) Stage
Stratification Factor: International Staging System (ISS) Stage(Participants)Bortezomib + DEXCarfilzomib + DEXTotal
Stage I204205409
Stage II or III261259520

1 further baseline measures are reported on the registry.

08

Study locations

241 sites
  • Providence St. Joseph Medical Center
    Burbank, California, United States
  • UCSD Moore Cancer Center
    La Jolla, California, United States
  • UCLA Medical Center
    Los Angeles, California, United States
  • Central Coast Medical Oncology Group
    Santa Maria, California, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado, United States
  • MAB Oncology/Hematology
    Melbourne, Florida, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida, United States
  • Winship Cancer Institute
    Atlanta, Georgia, United States
  • Hematology Oncology of Indiana, PC
    Indianapolis, Indiana, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland, United States
  • Associates in Oncology/Hematology PC
    Rockville, Maryland, United States
  • University of Michigan
    Ann Arbor, Michigan, United States
  • University of Kansas
    Kansas City, Missouri, United States
  • Hackensack University Medical Ctr
    Hackensack, New Jersey, United States
  • Montefiore Medical Center
    Bronx, New York, United States
  • Clinical Research Alliance Inc.
    New York, New York, United States
  • Weill Cornell Medical College
    New York, New York, United States
  • Wake Forest University Health Sciences, Section on Hematology and Oncology
    Winston-Salem, North Carolina, United States
  • Gabrail Cancer Center
    Canton, Ohio, United States
  • The Christ Hospital
    Cincinnati, Ohio, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania, United States
  • Hematology/Oncology Associates of SC
    Greenville, South Carolina, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee, United States
  • MD Anderson
    Houston, Texas, United States
  • The Methodist Cancer Center
    Houston, Texas, United States
  • Scott & White Memorial Hospital
    Temple, Texas, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales, Australia
  • St. Vincent's Public Hospital Sydney
    Darlinghurst, New South Wales, Australia
  • Saint George Hospital
    Kogarah, New South Wales, Australia
  • Liverpool Hospital
    Liverpool, New South Wales, Australia
  • Royal North Shore Hospital
    Saint Leonards, New South Wales, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales, Australia
  • Westmead Hospital
    Westmead, New South Wales, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland, Australia
  • Haematology & Oncology Clinics of Australia
    South Brisbane, Queensland, Australia
  • Haematology and Oncology Clinics of Australia at Chermside
    South Brisbane, Queensland, Australia
  • Haematology and Oncology Clinics of Australia at Wesley
    South Brisbane, Queensland, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • The Queen Elizabeth Hospital
    Woodville, South Australia, Australia
  • Box Hill Hospital
    Box Hill, Victoria, Australia
  • Monash Medical Centre
    Clayton, Victoria, Australia
  • Saint Vincent's Hospital
    East Melbourne, Victoria, Australia
  • Western Hospital
    Footscray, Victoria, Australia
  • The Alfred Hospital
    Melbourne, Victoria, Australia
  • Sunshine Hospital
    St. Albans, Victoria, Australia
  • Fremantle Hospital
    Fremantle, Western Australia, Australia
  • Royal Perth Hospital
    Perth, Western Australia, Australia
  • Medizinische Universität Innsbruck
    Innsbruck, Tyrol, Austria
  • Krankenhaus der Elisabethinen Linz, I Interne Abteilung
    Linz, Upper Austria, Austria
  • Wilhelminenspital der Stadt Wien
    Wien, Vienna, Austria
  • Universitair Ziekenhuis Leuven
    Leuven, Flemish Brabant, Belgium
  • Cliniques Universitaires UCL de Mont-Godinne
    Yvoir, Namur, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Oost-vlaanderen, Belgium
  • Ziekenhuis Netwerk Antwerpen
    Antwerp, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, Belgium
  • Universitair Ziekenhuis Brussel
    Brussels, Belgium
  • Liga Norte Riograndense Contra o Câncer
    Natal, RIO Grande DO Norte, Brazil
  • Clínica de Oncologia de Porto Alegre
    Porto Alegre, RIO Grande DO SUL, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, RIO Grande DO SUL, Brazil
  • Hospital São Lucas da PUCRS
    Porto Alegre, RIO Grande DO SUL, Brazil
  • Hemocentro Campinas-Unicamp
    Campinas, SAO Paulo, Brazil
  • Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro
    Rio de Janeiro, Brazil
  • Instituto Centros Oncológicos Integrados de Educação e Pesquisa
    Rio de Janeiro, Brazil
  • Instituto Nacional do Câncer-INCA
    Rio de Janeiro, Brazil
  • Irmandade da Santa Casa de Misericórdia de São Paulo
    São Paulo, Brazil
  • Military Medical Academy Hospital for Active Treatment
    Sofia, Sofiya, Bulgaria
  • Shato, Ead
    Sofia, Sofiya, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
    Plovdiv, Bulgaria
  • Multiprofile Hospital for Active Treatment, "Sveta Marina''
    Varna, Bulgaria
  • University of Alberta Hospital
    Edmonton, Alberta, Canada
  • British Columbia Cancer Agency
    Kelowna, British Columbia, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick, Canada
  • Queen Elizabeth II Health Science Centre
    Halifax, Nova Scotia, Canada
  • London Health Sciences Centre
    London, Ontario, Canada
  • The Ottawa Hospital Regional Cancer Centre
    Ottawa, Ontario, Canada
  • Windsor Regional Hospital
    Windsor, Ontario, Canada
  • Hopital Maisonneuve-Rosemont
    Montréal, Quebec, Canada
  • Fakultní nemocnice Královské Vinohrady
    Praha 10, Praha, Czechia
  • Fakultní nemocnice Olomouc
    Olomouc, Severomoravsky KRAJ, Czechia
  • FN Ostrava
    Ostrava, Severomoravsky KRAJ, Czechia
  • Fakultní nemocnice Hradec Králové
    Hradec Kralové, Vychodocesky KRAJ, Czechia
  • Fakultní nemocnice Brno
    Brno, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Praha, Czechia
  • Centre Hospitalier de la Cote Basque
    Bayonne, Aquitaine, France
  • Centre Hospitalier Universitaire Brest
    Brest Cedex, Bretagne, France
  • Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou
    Rennes Cedex 9, Bretagne, France
  • Hopital Hotel-Dieu - Service d'Hematologie
    Nantes, Cedex 1, France
  • Centre Henri-Becquerel
    Rouen Cedex 1, Haute-normandie, France
  • Centre Hospitalier de Versailles
    Le Chesnay, Ile-de-france, France
  • Hôpital Saint Louis
    Paris, Ile-de-france, France
  • Hôpital Saint-Antoine
    Paris, Ile-de-france, France
  • Hôpital Claude Huriez
    Lille Cedex, NORD Pas-de-calais, France
  • Hôpital Hôtel-Dieu
    Nantes cedex 1, PAYS DE LA Loire, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, Provence Alpes COTE D'azur, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite Cedex, Rhone-alpes, France
  • Universitätsklinik Heidelberg
    Heidelberg, Baden-wuerttemberg, Germany
  • Universitätsklinikum Tübingen
    Tübingen, Baden-wuerttemberg, Germany
  • Universitätsklinikum Ulm
    Ulm, Baden-wuerttemberg, Germany
  • Medizinische Klinik der Universität Würzburg
    Würzburg, Bayern, Germany

Showing the first 100 of 241 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hajek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017 Jan;31(1):115-122. doi: 10.1038/leu.2016.186. Epub 2016 Jul 4. PubMed 27491641 ↗
  • Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hajek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. doi: 10.1038/leu.2016.390. Epub 2016 Dec 27. PubMed 28025582 ↗
  • Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Erratum In: Lancet Oncol. 2017 Oct;18(10):e562. doi: 10.1016/S1470-2045(17)30721-0. PubMed 28843768 ↗
  • Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. No abstract available. PubMed 28306371 ↗
  • Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. PubMed 29991494 ↗
  • Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, Kimball AS, Mezzi K, Ludwig H, Niesvizky R. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2019 Jan 10;133(2):147-155. doi: 10.1182/blood-2018-06-860015. Epub 2018 Nov 26. PubMed 30478094 ↗
  • Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965. PubMed 33166401 ↗
  • Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017 Dec;31(12):2630-2641. doi: 10.1038/leu.2017.122. Epub 2017 Apr 25. PubMed 28439109 ↗
  • Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):9-22. doi: 10.1016/j.clml.2018.08.016. Epub 2018 Sep 5. PubMed 30287200 ↗
  • Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0. PubMed 30796199 ↗
  • Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15. PubMed 29446103 ↗
  • Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28. PubMed 32108443 ↗
  • Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6. PubMed 31388932 ↗
  • Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22. PubMed 28937327 ↗
  • Jakubowiak AJ, Houisse I, Majer I, Benedict A, Campioni M, Panjabi S, Ailawadhi S. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 Dec;10(12):1107-1119. doi: 10.1080/17474086.2017.1391088. PubMed 29027825 ↗
  • Weisel K, Mateos MV, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia. 2021 Jun;35(6):1732-1744. doi: 10.1038/s41375-020-01049-5. Epub 2020 Oct 16. PubMed 33067574 ↗
  • Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, Dimopoulos M. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Leuk Lymphoma. 2020 Jan;61(1):37-46. doi: 10.1080/10428194.2019.1648806. Epub 2019 Oct 22. PubMed 31640435 ↗
  • Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2. PubMed 31160237 ↗
  • Majer IM, Castaigne JG, Palmer S, DeCosta L, Campioni M. Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology. Pharmacoeconomics. 2019 May;37(5):727-737. doi: 10.1007/s40273-018-0759-6. PubMed 30610657 ↗
  • Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15;6(1):e384. doi: 10.1038/bcj.2015.112. PubMed 26771810 ↗
  • Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. PubMed 26671818 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Nov 2014, 28 months.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 28 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2012
First posted
Apr 2, 2012
StartActual
Jun 20, 2012
Primary completionActual
Nov 10, 2014
CompletionActual
Feb 5, 2018
Results first posted
Dec 11, 2015
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01568866
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Jun 20, 2012
Primary completion
Nov 10, 2014
Completion
Feb 5, 2018
Results posted
Dec 11, 2015
Last update
Nov 14, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion